U3 Pharma AG
Division of Daiichi Sankyo Co. Ltd.
Latest From U3 Pharma AG
Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Daiichi Sankyo has unveiled disappointing results for one pipeline molecule that has now been suspended for lung cancer, but has gained another for breast cancer as it continues to develop its oncology portfolio.
"I love it when a plan comes together," Hannibal Smith of TV show The A-Team used to say, a catchphrase which Daiichi Sankyo will be hoping is appropriate in around five years' time as it looks back on the results of its new mid-term strategy.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Daiichi Sankyo Co. Ltd.
- Senior Management
Irina Staatz-Granzer, PhD, CEO
Mike Rothe, PhD, CSO
- Contact Info
U3 Pharma AG
Phone: (49) 89 8103 90
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.